ASTHMA

RESPIRATORY

Managing Severe Asthma and CRSwNP through the lens of type 2 inflammation

EAACI Satellite Symp. Video Recording : Type 2 Inflammation.

<h2>A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy with Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients with Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin &amp;Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial</h2>
Soon Jun Hong, Han Saem Jeong, Jeong Cheon Ahn, Dong-Hun Cha, Kyung Heon Won, Weon Kim, Sang Kyoon Cho, Seok-Yeon Kim, Byung-Su Yoo, Ki Chul Sung, Seung-Woon Rha, Joon-Han Shin, Kyoo Rok Han, Wook Sung Chung, Min Su Hyon, Han Cheol Lee, Jang-Ho Bae, Moo-Yong Rhee, Jun Kwan, Dong Woon Jeon, Ki Dong Yoo, Hyo-Soo Kim

<h2>Objective</h2>
Combination therapy with ezetimibe and statins is recommended in cases of statin intolerance or insufficiency. The objective of this study was to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus those of rosuvastatin monotherapy in patients with hypercholesterolemia.

<h2>Endpoints</h2>
The primary endpoint was to evaluate the efficacy of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy by comparing the mean percent change from baseline in LDL-C level after 8 weeks of treatment.
The secondary endpoints were the mean percent change from baseline in the following: (1) total cholesterol (TC), TG, HDLC, non–HDL-C, apolipoprotein (Apo)B, and ApoA1; (2) high-sensitivity C-reactive protein (hs-CRP); and (3) LDL-C/HDL-C, TC/HDL-C, non–HDL-C/HDL-C, and Apo B/Apo A1 after 4 and 8 weeks of treatment.

<h2>Methods</h2>
I-ROSETTE was an 8-week, double-blind, multicenter, Phase III randomized controlled trial conducted at 20 hospitals in the Republic of Korea. Patients were Korean men and women aged between 19 and 79 years with hypercholesterolemia requiring medical treatment according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines were eligible for participation in the study.
Patients were randomly assigned to receive ezetimibe 10mg/rosuvastatin 20mg, ezetimibe 10mg/rosuvastatin 10mg, ezetimibe 10mg/rosuvastatin 5mg, rosuvastatin 20mg, rosuvastatin10mg, or rosuvastatin 5mg in a 1:1:1:1:1:1 ratio.

<h2>Results</h2>
A total of 396 patients were randomly assigned to receive ezetimibe 10mg/rosuvastatin 20mg (n = 67), ezetimibe 10mg/rosuvastatin 10 mg (n = 67), ezetimibe 10mg/rosuvastatin 5mg (n = 65), rosuvastatin20mg (n = 65), rosuvastatin 10 mg (n = 66), or rosuvastatin 5mg (n = 66).
After 8 weeks of double-blind treatment, the percent changes in adjusted mean LDL-C levels at week 8 compared with baseline values were -57.0% (2.1%) and -44.4% (2.1%) in the total ezetimibe/rosuvastatin and total rosuvastatin groups, respectively (P &lt; 0.001). The LDL-C-lowering efficacy of each of the ezetimibe/rosuvastatin combinations was superior to that of each of the respective doses of rosuvastatin. The number of patients who achieved target LDL-C levels at week 8 was significantly greater in the ezetimibe/rosuvastatin group (180 [92.3%] of 195 patients) than in the rosuvastatin monotherapy group (155 [79.9%] of 194 patients) (P &lt; 0.001).
The percent changes in TC, TG, non–HDL-C, and Apo B were also greater in the total ezetimibe/ rosuvastatin group than in the total rosuvastatin alone group. The changes in HDL-C and Apo A1 levels were not significantly different between the combination and monotherapy groups. The changes after 4 and 8 weeks in hs-CRP were similar between the combination and monotherapy groups.

<h2>Conclusion</h2>
Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level &gt;50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy.

Reference

The ROSETTE Study

DYSLIPIDEMIA

CARDIOLOGY

RESPIRATORY-SYNCYTIAL-VIRUS

VACCINES

2024 RSV International Congress ECMMID


<h3>Decoding RSV unveiling truths and myths in infant burden</h3>
Dr. Janak Patel 
 Director of Department of Infection Control &amp; Healthcare Epidemiology at UTMB, Texas, USA ECCMID congress, April 2024

2024 RSV International Congress - ESPID

<h3>Beyfortus, an innovative immunization for RSV disease prevention in infants</h3>
Dr Jason Terk, Senior Consultant - Vice-Chair for Primary Care, Cook Children's Physician Network, Texas, USA

Why is it important to measure FEV1 in patients with asthma?

Dupixent Asthma KOL Expert Series Video - Lung Function.

What's possible when their Child's Asthma is under control?

When the symptoms are not under control, the airways can become inflamed making breathing difficult. Whilst Asthma cannot be cured, the symptoms can be controlled enabling people with Asthma to live full lives.

What gives you confidence that Dupixent improves patients’ quality of life?

Dupixent Asthma KOL Expert Series Video - Quality of Life.

What feedback have you received from patients being treated with Dupixent?

Dupixent Asthma KOL Expert Series Video - DUPIXENT Patient Perspective.

What beneficial impact does Dupixent have on OCS-Dependent patients?

Dupixent Asthma KOL Expert Series Video - OCS-Sparing.

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles